看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
* m5 e5 a" ~2 F) }+ A z4 W/ z* E. o* D
( j2 G" [# Z4 Z |6 d. sCurrently available feasibility data for possible combination strategies.
) i# i3 V, X" o' P& b+ }( f J————————————————————————————————6 v4 x& H1 X+ n- J, S
Combination Feasibility according to preliminary data
3 i2 D5 G: a# L0 C. z0 F" g" H! g——————————————————————————————————
1 R) Q4 b& B0 }Bevacizumab + sorafenib Yes, reduced dose 5 A9 q+ J! o2 p" ] t4 V
Bevacizumab + sunitinib† No 3 `: u4 Y- ?/ w5 t6 a
Bevacizumab + temsirolimus Yes
) n) h3 t1 w3 v, L% x+ `: V8 k) aBevacizumab + everolimus Yes
" D# O* V/ _7 l$ v5 ` _2 nSorafenib + sunitinib ? : [4 `# F/ f+ d) g' i2 a# Q
Sorafenib + temsirolimus Yes, reduced dose 3 e2 V0 Y. r1 r1 s
Sorafenib + everolimus Yes, reduced dose / s% f$ C w2 N- p
Sunitinib + temsirolimus† No
& K* d9 A% D. L9 |Sunitinib + everolimus ? & C$ O' ?/ R8 X% t( Y$ S
Temsirolimus + everolimus ? 1 G( y5 i8 n x
————————————————————( q* J y, a! v
†Led to US FDA warning.7 n5 J G/ C* ?* A" d" O) M
?: As yet unattempted combination.
; M7 [# n8 s# T0 p( e3 c! k; ? |